Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Murthy Chamarthy

Vascular & Interventional Radiology Garland, TX Medical Doctor

NPI 1376854752 CMS profile 1338535

1919 S Shiloh Rd Ste 400, Garland, TX 75042

Open in the dashboard

General payments

$57,005

132 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Murthy Chamarthy of Garland, TX is reported in the CMS Open Payments database as having received $57,005 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $14,406 6
2023 General $17,051 30
2022 General $17,487 30
2021 General $6,186 27
2020 General $570 29
2019 General $1,306 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murthy Chamarthy
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Murthy Chamarthy were reported at $0. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Murthy Chamarthy Vascular & Interventional Radiology median Middle half National median
2019 $1,306 $422 $125–$1,555 $163
2020 $570 $200 $68–$652 $114
2021 $6,186 $280 $99–$866 $132
2022 $17,487 $433 $137–$1,497 $149
2023 $17,051 $506 $152–$2,019 $160
2024 $14,406 $556 $175–$1,930 $164
2025 $0 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AngioDynamics, Inc. $52,209 35 payments
  2. Cardiovascular Systems Inc. $1,431 15 payments
  3. Stryker Corporation $941 5 payments
  4. Philips Electronics North America Corporation $461 5 payments
  5. Abbott Laboratories $405 5 payments
  6. Inari Medical, Inc. $335 10 payments
  7. Medtronic, Inc. $330 16 payments
  8. Siemens Medical Solutions USA, Inc. $312 5 payments
  9. Medtronic Vascular, Inc. $294 22 payments
  10. Nevro Corp. $68 2 payments
  11. Other $218 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Long term medical supply or device loan $46,314 7 payments
  2. Education $4,667 1 payment
  3. Food and Beverage $3,154 108 payments
  4. Travel and Lodging $2,871 16 payments
Products named General payments · program years 2019–2024
  1. Auryon Laser System 100-120 Vac $51,138 10 payments
  2. Peripheral Orbital Atherectomy System $1,186 8 payments
  3. SPINEJACK $941 5 payments
  4. VenaCure 1470 Pro $739 2 payments
  5. CT THROMBECTOMY SYSTEM KIT $335 10 payments
  6. FLOWTRIEVER CATHETER, S $335 10 payments
  7. (9715) Azurion 5 M20 $320 3 payments
  8. TurboHawk Directional Atherectomy Devices $258 21 payments
  9. Diamondback Peripheral $228 6 payments
  10. TurboHawk Directional Atherectomy Devices $194 10 payments
  11. Other $1,621 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

29

Median for Interventional Radiology: 38

Drug cost

$182

Median for Interventional Radiology: $333

Branded share of claims

41.4%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 17 $107
Clopidogrel Clopidogrel Bisulfate Brand 12 $75

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 134 billing codes

Paid by Medicare

$57,085

Medicare's payments for the services billed

Medicare patients

841

Average age 74

Services billed

1,204

507 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 39%
Ischemic heart disease 38%
Chronic kidney disease 32%
Heart failure 31%
Depression 30%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record